Positron Emission Tomography/Computerized Tomography for the Gastroenterologist and Hepatologist

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 1, 2009, Pages 20-26

  Cronin, Carmel G ^a   Moore, Michael ^a   Blake, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GLUCOSE; UNCLASSIFIED DRUG; VOLUMEN;

ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; COLORECTAL CARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIET RESTRICTION; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG UPTAKE; ESOPHAGUS CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GALLBLADDER CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HEPATOBILIARY SYSTEM CANCER; HUMAN; LIVER CELL CARCINOMA; MEDICAL SPECIALIST; METASTASIS; MINIMAL RESIDUAL DISEASE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; POSITRON-EMISSION TOMOGRAPHY;

EID: 58049195284     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.10.033     Document Type: Article

References (53)

1. Bar-Shalom R., Guralnik L., Tsalic M., et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32 (2005) 918-924
2. Lerut T., Flamen P., Ectors N., et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 232 (2000) 743-752
3. Lowe V.J., Booya F., Fletcher J.G., et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 7 (2005) 422-430
4. Abdel-Dayem H.M., Rosen G., El-Zeftawy H., et al. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med 24 (1999) 319-322
5. Shankar L.K., Horffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18FFDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 47 (2006) 1059-1066
6. Hillner B.E., Liu D., Coleman R.E., et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med 48 (2007) 1901-1908
7. Blodgett T.M., Meltzer C.C., and Townsend D.W. PET/CT: form and function. Radiology 242 (2007) 360-385
8. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
9. Prabhakar H.B., Sahani D.V., Fischman A.J., et al. Bowel hot spots at PET-CT. Radiographics 27 (2007) 145-159
10. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22 (2004) 3805-3812
11. Pfau P.R., Perlman S.B., Stanko P., et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc 65 (2007) 377-384
12. Flanagan F.L., Dehdashti F., Siegel B.A., et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168 (1997) 417-424
13. Rice T.W. Clinical staging of esophageal carcinoma. CT, EUS, and PET. Chest Surg Clin N Am 10 (2000) 471-485
14. Kole A.C., Plukker J.T., Nieweg O.E., et al. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 78 (1998) 521-527
15. Cerfolio R.J., Bryant A.S., Ohja B., et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 129 (2005) 1232-1241
16. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 (2001) 3058-3065
17. Guo H., Zhu H., Xi Y., et al. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 48 (2007) 1251-1258
18. Valls C., Andía E., Sánchez A., et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 218 (2001) 55-60
19. Chua S.C., Groves A.M., Kayani I., et al. The impact of (18)F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 34 (2007) 1906-1914
20. Blake M.A., Singh A., Setty B.N., et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics 26 (2006) 1335-1353
21. Even-Sapir E., Parag Y., Lerman H., et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232 (2004) 815-822
22. Hung G.U., Shiau Y.C., Tsai S.C., et al. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 21 (2001) 1375-1378
23. Wiering B., Krabbe P.F., Jager G.J., et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104 (2005) 2658-2670
24. Votrubova J., Belohlavek O., Jaruskova M., et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 33 (2006) 779-784
25. Kim J.H., Czernin J., Allen-Auerbach M.S., et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 46 (2005) 587-595
26. Shoda H., Kakugawa Y., Saito D., et al. Evaluation of (18)F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 97 (2007) 1493-1498
27. Lim J.S., Yun M.J., Kim M.J., et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 26 (2006) 143-156
28. Rosenbaum S.J., Stergar H., Antoch G., et al. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging 31 (2006) 25-35
29. Sun L., Ye H.Y., Zhang Y.H., et al. Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection. World J Gastroenterol 13 (2007) 6115-6118
30. Goerres G.W., Stupp R., Barghouth G., et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32 (2005) 153-162
31. Gayed I., Vu T., Iyer R., et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45 (2004) 17-21
32. Alberini J.L., Al Nakib M., Wartski M., et al. [The role of PET scan in gastrointestinal stromal tumors]. Gastroenterol Clin Biol 31 (2007) 585-593
33. Antoch G., Kanja J., Bauer S., et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 45 (2004) 357-365
34. Böhm B., Voth M., Geoghegan J., et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 130 (2004) 266-272
35. Chua S.C., Groves A.M., Kayani I., et al. The impact of (18)F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 34 (2007) 1906-1914
36. Khan M.A., Combs C.S., Brunt E.M., et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32 (2000) 792-797
37. Sun L., Guan Y.S., Pan W.M., et al. Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management. World J Gastroenterol 13 (2007) 5413-5415
38. Koh T., Taniguchi H., Yamaguchi A., et al. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol 84 (2003) 74-81
39. Rodríguez-Fernández A., Gómez-Río M., Llamas-Elvira J.M., et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg 188 (2004) 171-175
40. Anderson C.D., Rice M.H., Pinson C.W., et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8 (2004) 90-97
41. Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 45 (2006) 43-50
42. Sun L., Wu H., and Guan Y.S. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 13 (2007) 2775-2783
43. Bang S., Chung H.W., Park S.W., et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40 (2006) 923-929
44. Heinrich S., Goerres G.W., Schäfer M., et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242 (2005) 235-243
45. Pakzad F., Groves A.M., and Ell P.J. The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36 (2006) 248-256
46. Veit-Haibach P., Kuehle C.A., Beyer T., et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 296 (2006) 2590-2600
47. Gollub M.J., Akhurst T., Markowitz A.J., et al. Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions. AJR Am J Roentgenol 188 (2007) 130-138
48. Herrmann K., Ott K., Buck A.K., et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48 (2007) 1945-1950
49. Plaza P., Montravers F., Aide N., et al. Assessment of a neuroendocrine tumour by 111In-pentetreotid scintigraphy and PET with 18FFDOPA and 18F-FDG. Rev Esp Med Nucl 23 (2004) 421-424
50. Kowalski J., Henze M., Schuhmacher J., et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5 (2003) 42-48
51. Das C.J., Makharia G., Kumar R., et al. PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imaging 34 (2007) 2106-2114
52. Vaglio A., and Buzio C. Chronic periaortitis: a spectrum of diseases. Curr Opin Rheumatol 17 (2005) 34-40
53. Drieskens O., Blockmans D., van den Bruel A., et al. Riedel's thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomography findings. Clin Nucl Med 27 (2002) 413-415